In infected INS-1 cells, and in glioma-conditioned-medium-stimulated ECs, PD98059, a specific MEK1 kinase inhibitor, significantly reduced cPLA2 enzyme activity [103,104,105]. This evidence concerns the gene MAP2K1 and central nervous system cancer.